纳米银对小鼠H22肝癌腹水瘤抑制作用的实验研究OACSTPCD

Objective:To investigate the effectiveness and safety of silver nanoparticles(Ag-NPs)treating H22 hepatoma ascites of mice via intraperitoneal injection.Methods:H22 cells were intraperitoneally injected in 40 Kunming mice for 12 consecutive days to set up a hepatoma ascites model.The Kunming mice were,thereby,assigned to the model group(normal saline),the cisplatin group,the low-Ag-NPs group,the medium-Ag-NPs and the high-Ag-NPs group.We observed the performance status,weight,abdomen circumference,ascites growth and survival of the mice.Another 20 healthy mice injected intraperitoneally with corresponding drugs for 12 consecutive days were further assigned to the control group and the high-Ag-NPs group for drug safety assessment.The weight and survival of the mice were observed.Hematology and biochemical indexes of the mice were detected by automatic blood cell analyzer and automatic biochemical analyzer.Results:Compared to the model group,the weight and abdomen circumference increased slowly and the survival prolonged in the Ag-NPs groups,and there were no significant differences be-tween the high-Ag-NPs group and the cisplatin group in weight,abdomen circumference and survival of the mice.The results of the drug safety assessment showed that there were no significant differences between the blank control group and the high-Ag-NPs group in weight,survival,hematology and biochemical indexes of the mice.Conclusion:Ag-NPs can suppress the growth of ascites and improve the survival of ascites mice without evident side effects,which can be a new method to cure hepatoma ascites.